摘要
肝细胞癌(hepatocellular carcinoma,HCC)是导致癌症相关死亡的第四大原因,仅次于肺癌、结直肠癌和胃癌.目前,化疗耐药是临床治疗肝癌患者的主要难题,也是导致患者预后不佳和高复发率的主要原因.肝癌耐药发生有多种因素,机制复杂.近年来研究显示,非编码核糖核酸(non-coding RNA,ncRNA)与肝癌化疗耐药有着密切关系,通过调控靶基因的表达和蛋白质的翻译,影响肝癌的发生、转移和预后,有望成为肝癌治疗的标志物和潜在的药物治疗靶点.因此,该文就几种常见的ncRNAs,包括长链非编码RNAs(long non-coding RNAs,LncRNAs),微小RNA(microRNAs)和转运RNA(transferRNA,tRNAs),在肝癌化疗耐药的分子机制和研究进展方面作一综述,为解决肝癌化疗耐药问题提供新思路.
Abstract
Hepatocellular carcinoma(HCC)is the fourth leading cause of cancer-related death,following lung cancer,colorectal cancer and gastric cancer.Chemoresistance is currently the major challenge in clinical treatment of HCC patients,and it is also the primary cause of the poor prognosis and high recurrence rate of patients.There are multiple factors and complex mechanisms in the occurrence of HCC drug resistance.Recent research has shown that non-coding RNA(ncRNA)is closely related to HCC chemoresistance.By regulating the expression of target genes and protein translation,ncRNA affects the occurrence,metastasis,and prognosis of HCC and is expected to become a therapeutic biomarker and potential drug therapeutic target for HCC.Therefore,this study reviews several common ncRNAs,including long non-coding RNAs(LncRNAs),miRNAs and transferRNA(tRNAs),in the molecular mechanisms and research progress of HCC chemoresistance,providing new ideas for solving the problem of HCC chemoresistance.
基金项目
上海市浦东新区卫生健康委重要薄弱学科建设项目(PWZbr2022-08)
浦东新区科技发展基金事业单位民生科研专项(PKJ2023-Y02)
上海中医药大学附属第七人民医院人才培养计划(XX2022-03)
维普
万方数据